Hémoglobine et hémoglobinopathies à l’avant-garde au xxie siècle (notice n° 659598)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02317cam a2200241 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121191941.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Beuzard, Yves |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Hémoglobine et hémoglobinopathies à l’avant-garde au xxie siècle |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 2 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Cette revue a pour but de faire le point des avancées récentes et des perspectives dans différents domaines (physiologiques, physiopathologiques et thérapeutiques) de l’hémoglobine et des hémoglobinopathies. À savoir : les gaz transmetteurs de signaux (NO, CO, H2S) ; l’ajustement du débit sanguin des « unités microcirculatoires » ; l’orchestration métabolique du globule rouge et au-delà ; la régulation « étagée » de l’expression et de la concentration intracellulaire d’une protéine modèle ; le contrôle de la différenciation et de la masse cellulaire d’un tissu ou organe ; la commutation de gènes lors du développement et sa réversion thérapeutique ; « la prise en charge globale » des patients drépanocytaires ou β-thalassémiques ; les agents thérapeutiques ciblés, les allogreffes et la thérapie génique par addition ou édition de gènes. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This review aims to take stock of recent advances and perspectives in various fields (physiology, physiopathology, and therapy) of haemoglobin and haemoglobin disorders. This includes gaseous signalling molecules (NO, CO, H2S), blood flow changes in microcirculatory units, metabolic regulation of red blood cells, etc., the regulatory stages that determine the expression and intracellular concentration of a model protein, control of differentiation and cell mass of a tissue or organ, gene switching during development and its therapeutic reversion, comprehensive care of patients with sickle cell disease or β-thalassaemia, targeted therapies, allo-transplantation, and gene therapy (gene addition or gene editing) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thalassémie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | drépanocytose |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Hémoglobine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Hemoglobin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thalassemia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | sickle cell disease |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 27 | 2 | 2021-03-01 | p. 55-77 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2021-2-page-55?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2021-2-page-55?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux